GNPX
Genprex, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Genprex, Inc.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Genprex, Inc.
2.30
+0.07 · +3.14%
+97.69%
shares held · 10 largest managers
No changes.
No changes.
No trades yet today.
No trades yet today.
| Manager | Value | % base | |
|---|---|---|---|
| Vanguard Fiduciary Trustindex-like | $40,536 | 26.26% | new |
| HRT Financial | $37,000 | 23.97% | new |
| Geodeindex-like | $31,319 | 20.29% | +80.83% |
| Vanguardindex-like | $18,866 | 12.22% | +510.92% |
| Engineers Gate Manager | $10,839 | 7.02% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguard Fiduciary Trustindex-like | $40,536 | 26.26% | new |
| HRT Financial | $37,000 | 23.97% | new |
| Geodeindex-like | $31,319 | 20.29% | +80.83% |
| Vanguardindex-like | $18,866 | 12.22% | +510.92% |
| Engineers Gate Manager | $10,839 | 7.02% | new |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Genprex, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Genprex, Inc..
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.